Alzheimer's disease trials recruiting in New Jersey

All Alzheimer's disease trials nationally

Cities in New Jersey

Recruiting trials in New Jersey

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New Jersey: Ridgewood, Springfield, Toms River
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New Jersey: Springfield
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
  NCT06297590 · Phase: Phase 1 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New Jersey: Toms River
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Toms River
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Middletown, Princeton
• A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
  NCT06810960 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · New Jersey: Nutley
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · New Jersey: Springfield
• A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
  NCT06657768 · Phase: Phase 1 · Ages: 45 Years to 85 Years · Sex: All (male and female) · New Jersey: Marlton
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New Jersey: Ridgewood
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
  NCT06651567 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · New Jersey: Toms River
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · New Jersey: Toms River
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: West Long Branch
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Toms River
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · New Jersey: Toms River
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · New Jersey: Ridgewood, Springfield, West Long Branch
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Princeton
• ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
  NCT07392723 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · New Jersey: New Brunswick
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New Jersey: New Brunswick
• Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
  NCT06189963 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · New Jersey: Newark
• Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
  NCT06052254 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · New Jersey: Toms River
• Exercise to Improve Brain Health in Older African Americans
  NCT05597124 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · New Jersey: Newark
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New Jersey: Toms River
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Toms River
• Open-label Extension Study in Participants With Early Alzheimer's Disease
  NCT07105709 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New Jersey: Toms River
• Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
  NCT05295615 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 100 Years · Sex: All (male and female) · New Jersey: Hackensack
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New Jersey: Ridgewood, Springfield
• Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
  NCT06847321 · Phase: Phase 2 · Ages: 55 Years to 80 Years · Sex: All (male and female) · New Jersey: Toms River
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New Jersey: Livingston, Toms River
• Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
  NCT07012993 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · New Jersey: Englewood